Autosome

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, November 22, 2022
Observation, Restaurant, DoorDash, Tripura Merger Agreement, A1AT, Bloomberg, Risk, Autosome, Class Action, Defendant, Class, Registration statement, BID, ADS, PayPal, P.C, Farm, NNA, Patient, Prospectus, Register, CNTA, SCH, Churn, PYPL, Growth, Polycystic kidney disease, DNA, Partnership, News, NYSE, Form, Fraud, Initial, Liver, Acquisition, AATD, Complaint, IPO, AE, Holding company, Food delivery, Risk management, Audit, Medical device, Security (finance), Animal, Renewable energy, Cryptocurrency, Online shopping, Opendoor, Subway, Algorithm, Mergers and acquisitions

Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.

Key Points: 
  • Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.
  • By the first quarter of 2022, the Companys active locations had grown to approximately 82,000 a 19% increase over the prior year.
  • For more information on the Opendoor class action go to: https://bespc.com/cases/OPEN
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Centessa Pharmaceuticals plc of Class Action Lawsuit and Upcoming Deadline – CNTA

Retrieved on: 
Thursday, November 17, 2022
Observation, AATD, LLP, A1AT, Polycystic kidney disease, DNA, American depositary receipt, Pomerantz, Autosome, Patient, Person, Complaint, IPO, Prospectus, Court, Ext, Registration statement, Defendant, Register, CNTA, AE, District court, News, BID, Class, ADS, Form, Liver, Security (finance), Pharmaceutical industry, Animal

NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (Centessa or the Company) (NASDAQ: CNTA) and certain of its officers and directors.

Key Points: 
  • NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (Centessa or the Company) (NASDAQ: CNTA) and certain of its officers and directors.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, November 17, 2022
Observation, Restaurant, DoorDash, Tripura Merger Agreement, A1AT, Bloomberg, Risk, Autosome, Class Action, Defendant, Class, Registration statement, BID, ADS, PayPal, P.C, Farm, NNA, Patient, Prospectus, Register, CNTA, SCH, Churn, PYPL, Growth, Polycystic kidney disease, DNA, Partnership, News, NYSE, Form, Fraud, Initial, Liver, Acquisition, AATD, Complaint, IPO, AE, Holding company, Food delivery, Risk management, Audit, Medical device, Security (finance), Animal, Renewable energy, Cryptocurrency, Online shopping, Opendoor, Subway, Algorithm, Mergers and acquisitions

Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.

Key Points: 
  • Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.
  • By the first quarter of 2022, the Companys active locations had grown to approximately 82,000 a 19% increase over the prior year.
  • For more information on the Opendoor class action go to: https://bespc.com/cases/OPEN
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer

Retrieved on: 
Wednesday, November 16, 2022
COVID-19, Unitary state, Kidney disease, Columbia University, Kidney, Wall Street, Polycystic kidney disease, Executive MBA Council, Uric acid, Autosome, Medtech, Therapy, Oxipurinol, Trust, TSX Venture Exchange, MBA, Patient, Coronavirus, Xanthine oxidase, ADPKD, Health, DS, Patent, News, Chronic kidney disease, McGill University, Diabetic nephropathy, Form, Quality of life, Pharmaceutical industry, Management, Pfizer, EU

CALGARY, Alberta, Nov. 16, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Stacy Evans, M.D., MBA, as Chief Business Officer.

Key Points: 
  • CALGARY, Alberta, Nov. 16, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Stacy Evans, M.D., MBA, as Chief Business Officer.
  • For the past seven years, Dr. Evans has consulted at an executive level with small to mid-size private and public biopharmaceutical companies, including acting as Chief Business Officer for many clients.
  • Allen Davidoff, Ph.D., Chief Executive Officer of XORTX, stated, We are pleased to welcome Stacy to the team as Chief Business Officer.
  • Dr. Evans brings extensive large and small pharma licensing and M&A experience to XORTX and will lead our increasingly active commercial assessment and business development activities.

CENTESSA PHARMACEUTICALS PLC (NASDAQ: CNTA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Centessa Pharmaceuticals plc (NASDAQ: CNTA)

Retrieved on: 
Tuesday, November 15, 2022
Observation, Central District, AATD, A1AT, Polycystic kidney disease, DNA, American depositary receipt, Labour government, Autosome, Patient, IPO, Class, Prospectus, Defendant, Court, Registration statement, The Legal 500, Register, CNTA, AE, Investment, District court, News, BID, ADS, Form, Advertising, Liver, Pharmaceutical industry, Security (finance)

NEW YORK, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or otherwise acquired: (a) Centessa Pharmaceuticals plc (“Centessa” or the “Company”) (NASDAQ: CNTA) American Depositary Shares (“ADSs”) pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about May 28, 2021 (the “IPO” or “Offering”); and/or (b) Centessa securities between May 28, 2021 and June 1, 2022, both dates inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Act of 1933 and Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Centessa Pharmaceuticals plc Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Centessa is a clinical-stage pharmaceutical company that purports to discover, develop, and deliver medicines to patients.
  • Plaintiff alleges that Defendants made materially false and misleading statements in the Offering Documents and throughout the Class Period.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

CENTESSA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals Plc and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, November 26, 2022
Class Action Lawsuit, Professional Services, Legal, P.C, Observation, Central District, AATD, A1AT, Polycystic kidney disease, DNA, Telephone, Jeanne Eagels, Autosome, Patient, Person, Class, IPO, Defendant, Prospectus, Court, Registration statement, Register, CNTA, AE, District court, News, BID, ADS, Form, Liver, Security (finance), Animal

Investors have until November 28, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until November 28, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Centessa is a clinical-stage pharmaceutical company that purports to discover, develop, and deliver medicines to patients.
  • Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.
  • As of the time the complaint was filed, Centessas ADS price continues to trade significantly below the $20.00 per ADS Offering price, damaging investors.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, November 12, 2022
Securities Act of 1933, Observation, Register, NASDAQ, CNTA, DoorDash, PayPal, Class Action, Churn, BID, AATD, Autosome, Growth, OLO, Warner, Company, Investment, Farm, Warner Bros., PYPL, NNA, Acquisition, Defendant, HBO Max, U.S. Securities and Exchange Commission, Section 11 of the Canadian Charter of Rights and Freedoms, Registration statement, A1AT, Polycystic kidney disease, Mergers and acquisitions, Prospectus, IPO, Complaint, GLOBE, Class, Patient, AE, Fraud, DNA, HBO, Contract, Form, ADS, AT&T, AT, SEC, News, Liver, Partnership, NYSE, Restaurant, Music, Audit, Food delivery, Risk management, Security (finance), Animal, Online shopping, Discovery, P.C, Subway, WarnerMedia

Discovery, Inc. (NASDAQ: WBD), Olo, Inc. (NYSE: OLO), Centessa Pharmaceuticals Plc (NASDAQ: CNTA), and PayPal Holdings, Inc. (NASDAQ: PYPL).

Key Points: 
  • Discovery, Inc. (NASDAQ: WBD), Olo, Inc. (NYSE: OLO), Centessa Pharmaceuticals Plc (NASDAQ: CNTA), and PayPal Holdings, Inc. (NASDAQ: PYPL).
  • For more information on the Warner Bros. class action go to: https://bespc.com/cases/WBD
    Olo provides software to restaurants to assist with online ordering and food-delivery coordination.
  • For more information on the PayPal class action go to: https://bespc.com/cases/PYPL
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

CENTESSA PHARMACEUTICALS PLC (NASDAQ: CNTA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Centessa Pharmaceuticals plc (NASDAQ: CNTA)

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Investment, Company, Polycystic kidney disease, A1AT, AE, Prospectus, The Legal 500, Securities Act of 1933, Defendant, DNA, SEC, Advertising, Form, NASDAQ, News, AATD, Securities Exchange Act of 1934, BID, American, IPO, Observation, Autosome, Court, Liver, District court, ADS, Patient, Register, NEW, Labour government, Central District, Registration statement, American depositary receipt, CNTA, Pharmaceutical industry, Security (finance)

NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or otherwise acquired: (a) Centessa Pharmaceuticals plc (“Centessa” or the “Company”) (NASDAQ: CNTA) American Depositary Shares (“ADSs”) pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about May 28, 2021 (the “IPO” or “Offering”); and/or (b) Centessa securities between May 28, 2021 and June 1, 2022, both dates inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Act of 1933 and Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Centessa Pharmaceuticals plc Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Centessa is a clinical-stage pharmaceutical company that purports to discover, develop, and deliver medicines to patients.
  • Plaintiff alleges that Defendants made materially false and misleading statements in the Offering Documents and throughout the Class Period.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Centessa Pharmaceuticals plc of Class Action Lawsuit and Upcoming Deadline – CNTA

Retrieved on: 
Monday, November 7, 2022
GLOBE, Complaint, Pomerantz, Company, Polycystic kidney disease, A1AT, AE, LLP, Prospectus, Person, Defendant, Securities Act of 1933, Class, DNA, SEC, Form, NASDAQ, News, U.S. Securities and Exchange Commission, Ext, Securities Exchange Act of 1934, AATD, BID, IPO, Observation, Autosome, Court, Liver, District court, ADS, Patient, American depositary receipt, Register, Registration statement, CNTA, Security (finance), Pharmaceutical industry, Animal

NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (Centessa or the Company) (NASDAQ: CNTA) and certain of its officers and directors.

Key Points: 
  • NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (Centessa or the Company) (NASDAQ: CNTA) and certain of its officers and directors.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, November 7, 2022
DNA, AATD, Fraud, DoorDash, U.S. Securities and Exchange Commission, Churn, Partnership, Acquisition, Form, Technology, SEC, Class, Bloomberg, Company, Prospectus, Growth, GLOBE, NYSE, IPO, SCH, Autosome, Tripura Merger Agreement, Initial, BID, Registration statement, Nasdaq, Polycystic kidney disease, Patient, PayPal, A1AT, Contract, Complaint, Farm, CNTA, Review, Defendant, ADS, Observation, AE, P.C, Class Action, Restaurant, Industry, PYPL, NNA, Register, NASDAQ, Risk, Liver, News, Holding company, Food delivery, Risk management, Audit, Medical device, Security (finance), Animal, Renewable energy, Cryptocurrency, Online shopping, Mergers and acquisitions, Subway, Opendoor, Algorithm

Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.

Key Points: 
  • Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.
  • By the first quarter of 2022, the Companys active locations had grown to approximately 82,000 a 19% increase over the prior year.
  • For more information on the Opendoor class action go to: https://bespc.com/cases/OPEN
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.